Multimillion-dollar prices for gene therapies are fair, Vertex CEO says

How much should a one-time treatment with the potential to cure diseases like sickle cell disease, which can cost millions of dollars to treat over a life time, cost? Millions, indeed, says Vertex CEO Stuart Arbuckle.

Photo: Brian Snyder/Reuters/Ritzau Scanpix

Multimillion-dollar prices for a rival’s treatments with the potential to cure rare diseases are “in the right ballpark,” according to Stuart Arbuckle, chief operating officer of Vertex Pharmaceuticals Inc., which is preparing to market its own treatment for sickle-cell disease.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs